297 results about "Pulmonary adenocarcinoma" patented technology

The invention provides methods for detecting single nucleotide variants in lung cancer, especially stage 3a lung adenocarcinoma and lung squamous cell carcinoma. Additional methods and compositions, such as reaction mixtures and solid supports comprising clonal populations of nucleic acids, are provided.

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.

The invention belongs to the field of biological and medicine examination, relates to a tumor biomarker, and in particular relates to an early-stage lung adenocarcinoma miRNA (micro ribonucleic acid) specific expression profile and a reverse transcription primer and an application thereof. The early-stage lung adenocarcinoma miRNA specific expression profile comprises more than one of up-regulated expression miR-103, miR-146a, miR-151, miR-221, miR-222 and miR-223. The invention provides an early-stage lung adenocarcinoma diagnosis model, a reverse transcription primer of specific expression miRNA and a kit or biochip for early-stage lung adenocarcinoma diagnosis based on the specific expression profile. The technical scheme provided by the invention can realize accurate diagnosis of early-stage lung adenocarcinoma by detecting a small amount of miRNA, and provides possibility to the production of accurate, efficient and economical detection products. The established lung adenocarcinoma prediction model can distinguish lung adenocarcinoma from a healthy individual, and has great practical significance in clinic.

Macrophages within the tumor microenvironment, also called tumor associated macrophages (TAMs) have been shown to play a major role in the growth and spread of many types of cancer. Cancer cells produce cytokines that cause the macrophages to differentiate into an M2 subtype. We have designed a mannosylated liposome (MAN-LIPs) and successfully showed it to accumulate in TAMs in a mouse model of pulmonary adenocarcinoma. These liposomes are loaded with 64Cu to allow tracking by PET imaging, and contain a fluorescent dye in the lipid bilayer permitting subsequent fluorescence microscopy. MAN-LIPs are a promising new vehicle for the delivery of imaging agents to lung TAMs. In addition to imaging, they hold the potential for delivery of therapeutic agents to the tumor microenvironment.

The present invention relates to epitope of CD66c specific to lung adenocarcinoma and antibody recognizing the same. The present invention relates to identifying epitope of CD66c specific to lung adenocarcinoma, antibody recognizing the same, cell lines producing the same and the applications in diagnosis, prevention and treatment of lung adenocarcinoma by using the same. The above CD66c epitope is specific to lung adenocarcinoma cells, and therefore the antibody or its fragment recognizing the epitope can be used in compositions to diagnose, treat and prevent lung adenocarcinoma cells.

The invention discloses a fly maggot extractive containing the principal components of water-soluble proteins, and the water-soluble proteins contained in the fly maggot extractive have the mass percentage of 50-70 percent and the molecular weight of 2-16 KDa. The fly maggot extractive not only has obvious inhibiting effect on human promyelocytic leukemia HL-60 cells, human erythroleukemia K562 cells, human liver cancers SMMC-7721, mouse leukemia P388 cells, human lung adenocarcinoma A549 cells, human nasopharyngeal darcinoma CNE cells, human prostatic carcinoma PC3 cells, human cervical carcinoma HeLa in vitro, but also has outstanding inhibiting effect on mouse S180 sarcomas and mouse Heps liver cancer solid tumors, and also has the effect on enhancing the humoral immunity of organisms. The invention also discloses a preparation method of the fly maggot extractive. The preparation method is easy and convenient for operation and control and low in cost and is suitable for industrialized production.

The invention provides a peripheral blood mRNA marker for predicting prognosis of patients with lung adenocarcinoma and a screening method and application thereof and belongs to the technical fields of medical molecular biology and clinical medicine. The screening method includes the steps of 1), comparatively analyzing gene expression profiles of wild-type human lung cancer cell lines and Nrf2 gene knockout human lung cancer cell lines to obtain Nrf2 target genes; 2), analyzing the relationship between Nrf2 target gene expression and the prognosis survival rate of lung adenocarcinoma by the aid of a discovery group database and screening out the genes with the Nrf2 target gene expression Wald statistics greater than 2 in the discovery group database to obtain the periphery blood MRNA marker for predicting prognosis of the patients with the lung adenocarcinoma. The marker obtained with the screening method is applied to predicting prognosis of the patients with clinical lung adenocarcinoma, good flexibility, stability and specificity are achieved, and spreading use can be realized.

The invention provides a micropapilla detection system based on YOLOv5. The micropapilla detection system comprises a lung adenocarcinoma pathological image acquisition module, a detection model training module and a micropapilla detection module; a feature extraction module in the detection model training module adds a layer of feature extraction on the basis of a BottleneckCSP network structure to obtain a shallow feature map, so that the multiple of downsampling of the feature extraction module is reduced by half; the feature fusion module is used for down-sampling the shallow feature map and splicing the shallow feature map with the deep feature map, so that the features of the shallow feature map and the deep feature map are fused, and the small target detection capability of the network is enhanced; and the prediction module replaces the GIoU loss with the CIoU loss, optimizes the prediction frame, improves the regression speed and precision of the prediction frame, and is more suitable for the detection of micronipples.

The invention relates to a quinoline multi-target kinase inhibitor with antitumor activity and a preparation method thereof. A general structural formula of the compound is shown in a formula (I) described in the specification. In vitro cell experiments verify that the compound provided by the invention has strong in vitro inhibitory activity on five common tumor cell lines, namely human thyroid carcinoma SW579, human hepatic carcinoma HepG2, human lung adenocarcinoma A549, human colorectal adenocarcinoma HCT116 and human gastric carcinoma MKN45, antitumor activities of most of target compounds are better than or equivalent to that of a positive control drug Cabozantinib, and the in vitro cell experiments verify that the compound provided by the invention has strong inhibitory activity on two kinases KDR and MET, so that the compound provided by the invention has a broad application prospect in preparation of a new antitumor drug.

The invention provides application of any one or more than two long non-coding RNAs to preparation of a lung adenocarcinoma diagnosing reagent. The LncRNA is LINC00942, LINC00973, AFAP1-AS1 or CLDN10-AS1, wherein the cDNA sequence of the LINC00942 long non-coding RNA is shown as SEQ ID NO.15; the cDNA sequence of the LINC00973 long non-coding RNA is shown as SEQ ID NO.16; the cDNA sequence of the AFAP1-AS1 long non-coding RNA is shown as SEQ ID NO.17; and the cDNA sequence of the CLDN10-AS1 long non-coding RNA is shown as SEQ ID NO.18. The LncRNA can be applied to lung adenocarcinoma diagnosis.

The invention discloses an N-alkyl-1,2,3,4,5,6-hexahydro-1,1,5,5-tetramethyl-7H-2,4 alpha-methanonaphthalene-7-amine compound as well as a synthetic method and an application thereof. Longifolene serving as a heavy oil main component is relatively rich terpenoid in numerous natural extracts. The synthetic method comprises the following steps: obtaining isolongifolene through longifolene isomerization, obtaining isolongifolenone through allylic oxidation of the isolongifolene, carrying out dehydration condensation on the isolongifolenone and primary amine so as to obtain imine and obtaining the chiral N-alkyl-1,2,3,4,5,6-hexahydro-1,1,5,5-tetramethyl-7H-2,4 alpha-methanonaphthalene-7-amine compound after reduction. The compound has vey good inhibition activity on candida albicans, aspergillus niger, candida tropicalis, escherichia coli, staphylococcus aureus, pseudomonas fluorescens, bacillus subtilis and the like, a part of compound has good cancer cell proliferation inhibition activity on human breast cancer cells MCF-7, human lung adenocarcinoma cells A549, hepatoma cells HepG2 and SMMC-7721, and the N-alkyl-1,2,3,4,5,6-hexahydro-1,1,5,5-tetramethyl-7H-2,4 alpha-methanonaphthalene-7-amine compound is a potential antibacterial and bactericidal and anti-tumor compound.

The invention relates to a composition related to lung adenocarcinoma metastasis and application thereof and particularly relates to novel application of the composition composed of one or more of the mir-193a, mir-3942, mir-767, mir-193b and mir-550a-1 and / or matures miRNA for diagnosing the lung adenocarcinoma metastasis. By performing sequencing analysis on the lung adenocarcinoma metastatic group and the non-metastatic group, a reserved drone gene is chosen to perform molecular biology verification. The result shows that the miRNA provided by the invention is closely related to the lung adenocarcinoma metastasis. The composition can be used for clinical diagnosis and preventive detection and has good practical application value.

The invention discloses a non-small cell lung cancer pathological section identification method based on a deep convolutional neural network. The method comprises the following steps: acquiring pathological sections of non-small cell lung cancer in a public data set from TCGA; constructing a deep learning model for training; inputting the training data set into a convolutional neural network for training to obtain a learned convolutional neural network model; and inputting the training data set into a convolutional neural network for training to obtain a learned convolutional neural network model. According to the method, the Inception-v3 model and the CBAM attention mechanism are fused together, so that the classification of the non-small cell lung cancer is realized, and the network precision is improved through the attention mechanism; meanwhile, a deep convolutional neural network Inception-v3 experimental result shows that the non-small cell lung cancer pathological section identification method based on deep learning provided by the invention can effectively classify lung adenocarcinoma and lung squamous cell carcinoma, reduces the burden of doctors to a certain extent, and realizes very good performance in the field of medical image identification.

Adenocarcinoma of the lung cell strain with bone transfer high potency and its construction are disclosed. The process is carried out by using human lung adenocarcinoma SPC-A-1 cell strain as source cell, immunizing deficiency mouse in vivo, externally continuously screening, image detecting from nuclein bone and constructing adenocarcinoma of the lung cell strain SPC-A-1 BM with bone transfer high potency. Its advantages include less cell volume, fast cell growth speed, better infiltration and transfer ability. It can be used for lung cancer transfer.

The invention provides lung adenocarcinoma exosome specific miRNAs, and a target gene and applications thereof. High flux sequencing technology is combined with systematic bioinformatics analysis methods, the specific high-content exosome miRNAs related with lung adenocarcinoma is obtained through screening; the RNA sequences of the lung adenocarcinoma exosome specific miRNAs are represented by SEQ ID No.1-3. It is found that the common target gene of the miRNAs is FOXN3. The target gene is capable of inhibiting fibroblast migration capability, reduction of the expression amount of the targetgene is capable of promoting entering of fibroblast into tumor tissues, and promoting tumor growth. The lung adenocarcinoma exosome specific miRNAs and the target gene thereof can be taken as lung adenocarcinoma diagnosis markers and can be used for preparation of diagnostic kits. An inhibitor of the miRNAs or an expression promoter of the target gene can be used for preparing medicines used for treating lung adenocarcinoma, or medication guidance in treatment of lung adenocarcinoma; and the clinical application value is relatively high, and the application prospect is promising.

The invention discloses a mark used for prediction of prognosis of a lung adenocarcinoma. The mark is composed of OPN3, GALNT2, FAM83A AND KYUN, and a mathematical model for prediction of prognosis ofthe lung adenocarcinoma is established based on the four indexes of OPN3, GALNT2, FAM83A AND KYUN, wherein the expression formula of the mathematical model is P=0.0004A+0.0042B+0.0055C+0.0077D, in the formula, P is a risk coefficient, A is the expression quantity of OPN3, B is the expression quantity of GALANT2, C is the expression quantity of FAM83A, and D is the expression quantity of KYNU. When P is higher than 0.216, it is defined to have a high risk, and otherwise it is defined to have a low risk. The prediction for AUC of the prognosis of the lung adenocarcinoma reaches 0.71 through themodel, when cut-off is 0.216, the sensitiveness of predicting a three-year overall life cycle of a patient with the lung adenocarcinoma is 53.3% through the mode, specificity is 82.9%, the average overall life cycle of patient groups with high risks of the lung adenocarcinoma is about 46 months, and the average overall life cycle of patient groups with low risks is about 94 months.

The invention discloses an auxiliary identification system and method for lung adenocarcinoma subtypes, and relates to a neural network. The system comprises an acquisition module for acquiring a digital pathological image and labeling to obtain a labeled image; wherein the features include lesion areas and real pathological image features; the processing module is used for processing the annotated image to obtain a processed image and storing the processed image into a database; the classification module divides the processed images into a training set, a verification set and a test set; thetraining module is used for training the training set to obtain an auxiliary identification model of the lung adenocarcinoma subtype; the verification module is used for inputting the verification setinto the auxiliary identification model for optimization to obtain an optimization model; the test module is used for inputting the test set into the optimization model to obtain a result and obtaintest accuracy; the comparison module is used for comparing the test accuracy with a test threshold value and retraining when the test accuracy is smaller than the test threshold value; and if not, storing the auxiliary identification optimization model. The kit has the beneficial effect of assisting a clinician in identifying the lung adenocarcinoma subtype.

The invention discloses a compound isolated from Antrodia camphorate and shown as formula I. Specifically, R1 is hydrogen or acetyl. The invention further discloses application of the compound to preparation of drugs for inhibiting tumor growth, wherein the tumor can be one of lung adenocarcinoma, colon cancer, prostate cancer and liver cancer.

The invention discloses a system for predicting prognosis of patients with lung adenocarcinoma and judging benefit of an adjuvant chemotherapy. The system comprises a system used for detecting expression quantities of six proteins, i.e., c-Src, Cyclin E1, TTF1, p65, CHK1 and JNK1, and a protein expression quantity data processing system. The system used for detecting the expression quantities of the six proteins can determine the expression quantities of the proteins by using an immunohistochemistry staining method; the protein expression quantity data processing system converts the expression quantities of the six proteins in lung adenocarcinoma tissues, separated from to-be-predicted patients with the lung adenocarcinoma, into a prognosis score, and predicting the prognosis of the to-be-predicted patients with the lung adenocarcinoma according to the prognosis score, and / or predicting whether the to-be-predicted patients with the lung adenocarcinoma are benefited from the adjuvant chemotherapy or not according to the prognosis score.

The invention discloses a human lung adenocarcinoma cell line and an application thereof. The human lung adenocarcinoma cell line is preserved at China Center for Type Culture Collection (CCTCC) on May 23th, 2014, in Wuhan University 430072, China. The name of a culture is human lung adenocarcinoma cell ZRLC-1; and a preservation number is CCTCC NO: C2014103. The human lung adenocarcinoma cell ZRLC-1 can be used as an experimental material in lung adenocarcinoma basic and clinical research, and can be used for establishing an animal model for occurrence, development and metastasis of lung cancers. The human lung adenocarcinoma cell line has stable characters, can be sub-cultured for a plurality of times stably, and can highly express epithelial markers such as EpCAM and E-cadherin. Flow cytometric analysis shows that EpCAM positive cells reach over 99.70%; and novel experiment material closer to the biological characteristics of clinical tumors are provided for the research of the lung cancers.

Provided are phenanthroindolizidine alkaloid derivates and salt thereof as well as preparation, a plant-virus resisting activity, and an anti-cancer activity of phenanthroindolizidine alkaloid derivates and salt thereof. The derivates and the salt thereof have a good plant-virus resisting activity, which is capable of well restraining a tobacco mosaic virus (TMV), and meanwhile, have a good anti-cancer activity, which is capable of well restraining the human lung adenocarcinoma A-549 and the human leukemia HL-60.

The invention belongs to the technical field of immunohistochemistry and relates to a double-labeled immunohistochemical staining kit for micro invasive lung adenocarcinoma. In order to solve the problem that invasive components and non-invasive components of micro invasive lung adenocarcinoma in HE staining films are difficultly distinguished clearly, the CD34 and beta-Tubulin-III double-labeled immunohistochemical staining kit is prepared and is applied to identification of the invasive lesions and the non-invasive components in the early stage of the lung adenocarcinoma, and overdiagnosis or under-diagnosis of the lung adenocarcinoma, caused by artificial interpretation difference, can be avoided.

The invention discloses application of an LOC101928926 gene which is used for preparing a product for diagnosing pulmonary adenocarcinoma. The invention further discloses application of the LOC101928926 gene in preparing or screening medicine for treating pulmonary adenocarcinoma. The LOC101928926 gene related to occurrence and development of pulmonary adenocarcinoma can serve as a biological marker of pulmonary adenocarcinoma to help a doctor make individualized treatment schemes, and meanwhile the pulmonary adenocarcinoma serves as a medicine target for treating tumors.

The human HLJ1 tumor suppressor gene is herein defined as regulated by promoter, enhancer, and silencer regions. HLJ1 promoter activity and gene expression are inversely correlated with metastatic ability. HLJ1 is highly expressed, and inducible, in cells with low metastatic ability and expressed to a lesser extent in highly metastatic cells. HLJ1 gene expression suppressed the growth of human lung adenocarcinoma cells in vitro, and inhibited tumor growth in vivo. It also impeded the motility of human adenocarcinoma cells and reduced the anchorage-independent growth capacity and invasiveness of metastatic lung adenocarcinoma cells. The degree to which human lung adenocarcinoma patients express HLJ1 predicts their survival prognosis and their probability of relapse.

The invention belongs to the filed of microorganism animal cell lines and provides a Chinese lung adenocarcinoma cell line with high metastases potentiality of bone, lever and adrenal gland. According to the invention, hydrothorax of an adenocarcinoma first-diagnosis patient is used as primary culture of cells; the human adenocarcinoma cell has the preservation number of CGMCC No.3137 and classified name as human lung adenocarcinoma cell line CPA-Yang3, can grow adhered to the wall and has the tumorigenesis rate up to 100 percent; the human lung adenocarcinoma cell can grow quickly and metabolize vigorously; the expression levels of cancer genes EMS1, VEGF-C, IL-6, IL-8, SVIL and AR gene are higher than the expression level of SPC-A-1 cell; and the lung adenocarcinoma cancel cell has the biological characteristics of mainly transferring the bone and having high transfer potential of the lever and the adrenal gland, high growth speed of bone transfer cells and complete cell morphology. The invention can be used for providing reference data to early diagnosis for transferring the human lung adenocarcinoma bone, further establishing the relevant gene chip technology and assessing and exploring the curative effects of various medicaments and the like by comprehensively applying the gene chip, quantifying PCR (Polymerase Chain Reaction), western blot in real time and other technologies.

The invention belongs to the technical field of biology, discloses a gene group capable of evaluating primary lung adenocarcinoma molecular typing and survival risk, and discloses application of reagents for detecting gene expression levels of the gene group in preparing in-vitro diagnostic products for evaluating primary lung adenocarcinoma molecular typing and survival risk. The in-vitro diagnostic products comprise a Next Generation Sequencing (NGS) detection kit, a fluorescent quantitative PCR detection kit, a gene chip and a protein array. The invention further discloses a method for evaluating primary lung adenocarcinoma molecular typing and survival risk by utilizing the detection kits. The method disclosed by the invention has high accuracy on evaluation of primary lung adenocarcinoma subtype typing and survival risk.

The invention discloses an aromatic hydrocarbon ruthenium complex and an application thereof as an antitumor drug. For the aromatic hydrocarbon ruthenium complex, methyl benzene is taken as a ligand, phenanthro-imidazole and derivatives of phenanthro-imidazole are taken as the second ligand, and a chlorine atom is taken as the third ligand. The complex can inhibit the propagation, invasion and metastasis of tumor cells, has an especially good effect on inhibiting growth of cells of breast cancer, brain glioma, leukemia, nasopharyngeal carcinoma, and pulmonary adenocarcinoma, and barely damages the normal cells of human body. The invention also discloses a preparation and applications of the aromatic hydrocarbon ruthenium complex.

The invention discloses a prognosis evaluation system for patients with early-stage LUAD and application thereof. According to the invention, disease-free survival data of 632 patients with early-stage LUAD in three independent queues are integrated, and an individual IBRS model for patients with early-stage LUAD is established and verified. The three independent queues include TCGA, GSE31210 and68 cases of frozen tissues. The IBRS model is composed of the following nine genes: DYNC1I2, THOC1, ADAM10, SERPINB6, CCL20, WNT2B, SLC11A1, MAPT and PSEN1. The establishment of the IBRS model for patients with early-stage LUAD is not only beneficial for understanding of the complex interaction mechanism between immune molecules, but also brings great help to the recurrence prediction of the patients with early-stage LUAD and the optimization of a treatment scheme.

The invention provides long-chain non-coding RNA and application thereof. Studies suggest that expression of LOC102724660 in lung adenocarcinoma tissue is obviously different from expression in para-carcinoma tissue. On this basis, it is concluded that LOC102724660 can serve as a molecular marker for diagnosing lung adenocarcinoma. Based on the fact that LOC102724660 is expressed at a low level in lung adenocarcinoma tissue and is over-expressed in lung adenocarcinoma cells, the function of LOC102724660 in lung adenocarcinoma is researched, and the result show that overexpression of LOC102724660 can inhibit the proliferation of lung adenocarcinoma cells remarkably. The key role of LOC102724660 in the lung adenocarcinoma pathogenesis is disclosed, and a novel molecular marker and drug target are provided for clinical diagnosis, treatment and prognosis monitoring of lung adenocarcinoma.